Cargando…

Predictors of response to erenumab after 12 months of treatment

OBJECTIVE: Erenumab is a monoclonal antibody acting against calcitonin gene‐related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baraldi, Carlo, Castro, Flavia Lo, Cainazzo, Maria Michela, Pani, Luca, Guerzoni, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413721/ https://www.ncbi.nlm.nih.gov/pubmed/34268907 http://dx.doi.org/10.1002/brb3.2260

Ejemplares similares

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
por: Guerzoni, Simona, et al.
Publicado: (2023)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal
por: Baraldi, Carlo, et al.
Publicado: (2017)

Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2017)

Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2018)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication–overuse headache
por: Pellesi, Lanfranco, et al.
Publicado: (2019)

Clinical Evidence of Cannabinoids in Migraine: A Narrative Review
por: Lo Castro, Flavia, et al.
Publicado: (2022)

P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse
por: Guerzoni, Simona, et al.
Publicado: (2015)

Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
por: Pilati, Laura, et al.
Publicado: (2023)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
por: Ornello, Raffaele, et al.
Publicado: (2022)

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
por: Pensato, Umberto, et al.
Publicado: (2022)

Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
por: Lowe, Michael, et al.
Publicado: (2022)

Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
por: Baraldi, Carlo, et al.
Publicado: (2021)

Association between response to triptans and response to erenumab: real-life data
por: Frattale, Ilaria, et al.
Publicado: (2021)

Basal cutaneous pain threshold in headache patients
por: Zappaterra, Maurizio, et al.
Publicado: (2011)

Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
por: Ornello, Raffaele, et al.
Publicado: (2019)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
por: Nowaczewska, Magdalena, et al.
Publicado: (2022)

A longitudinal clinical and MRI evaluation of the treatment with erenumab
por: Coccia, Alberto, et al.
Publicado: (2020)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
por: Torrisi, Michele, et al.
Publicado: (2023)

Occlusal splint therapy in patients with Ménière’s disease and temporomandibular joint disorder
por: Monzani, Daniele, et al.
Publicado: (2022)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
por: Tringali, Giuseppe, et al.
Publicado: (2020)

Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
por: Guerzoni, Simona, et al.
Publicado: (2016)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Lichenoid drug eruption induced by erenumab
por: Musicante, Meryl, et al.
Publicado: (2022)

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
por: De Icco, Roberto, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Impact of continuing or quitting smoking on episodic cluster headache: a pilot survey
por: Ferrari, Anna, et al.
Publicado: (2013)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
por: Jantzen, Frederik Thal, et al.
Publicado: (2023)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
por: Ornello, Raffaele, et al.
Publicado: (2021)

A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants
por: Bacchelli, Elena, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_45bab4nbs9lfl07b6phakn1jol